文献速递细菌感染、耐药与抗菌药物

欧盟动物中氨基糖苷类药物的使用:动物耐药性发展及对人类与动物健康可能影响

The use of aminoglycosides in animals within the EU: development of resistance in animals and possible impact on human and animal health: a review.
PubMed 文献 · J Antimicrob Chemother · 2019-01-01

本文综述了欧盟动物使用氨基糖苷类药物后耐药性的产生与传播。获得性耐药主要通过酶灭活机制,耐药基因常位于可移动遗传元件上,可在菌种及动物与人之间传播。风险评估认为动物源耐药经食物链细菌或可移动元件传播给人类的概率高,但缺乏定量数据。

要点

  • 氨基糖苷类耐药基因常位于可移动遗传元件,易跨菌种及跨物种传播。
  • 动物源耐药菌(如肠球菌、大肠杆菌)传播给人类的风险评估为高,但无定量数据。
  • 合理使用氨基糖苷类药物对保障人医和兽医临床疗效至关重要。

核心结论

  • 动物使用氨基糖苷类与人医使用均与耐药流行率增加相关,动物源耐药传播给人类的概率评估为高,但缺乏定量贡献数据。

研究设计与样本

  • 综述,检索并汇总欧盟动物使用氨基糖苷类后耐药发展及对人类和动物健康影响的文献。

主要发现

  • 获得性耐药机制中酶灭活最常见,耐药基因常位于可移动遗传元件。
  • 耐药已在多种细菌中发现,包括沙门菌、弯曲杆菌和牲畜相关MRSA。
  • 最高风险来自耐药肠球菌或大肠杆菌的传播,因人类感染这些病原体可能用氨基糖苷类治疗。
  • 人源和动物源分离株中发现了相同的耐药基因。

关键数值与推荐

  • 风险评估认为动物源耐药经人畜共患或共生食源性细菌和/或其可移动遗传元件传播给人类的概率高。
  • 原文未报告具体耐药率、阈值或定量传播贡献数据。

临床怎么用

  • 在人类和兽医临床中应负责任地使用氨基糖苷类,以保障其临床疗效。
  • 关注动物源肠球菌和大肠杆菌的氨基糖苷类耐药监测。

局限性

  • 缺乏动物对人源病原体氨基糖苷类耐药实际贡献的定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aminoglycosides (AGs) are important antibacterial agents for the treatment of various infections in humans and animals. Following extensive use of AGs in humans, food-producing animals and companion animals, acquired resistance among human and animal pathogens and commensal bacteria has emerged. Acquired resistance occurs through several mechanisms, but enzymatic inactivation of AGs is the most common one. Resistance genes are often located on mobile genetic elements, facilitating their spread between different bacterial species and between animals and humans. AG resistance has been found in many different bacterial species, including those with zoonotic potential such as Salmonella spp., Campylobacter spp. and livestock-associated MRSA. The highest risk is anticipated from transfer of resistant enterococci or coliforms (Escherichia coli) since infections with these pathogens in humans would potentially be treated with AGs. There is evidence that the use of AGs in human and veterinary medicine is associated with the increased prevalence of resistance. The same resistance genes have been found in isolates from humans and animals. Evaluation of risk factors indicates that the probability of transmission of AG resistance from animals to humans through transfer of zoonotic or commensal foodborne bacteria and/or their mobile genetic elements can be regarded as high, although there are no quantitative data on the actual contribution of animals to AG resistance in human pathogens. Responsible use of AGs is of great importance in order to safeguard their clinical efficacy for human and veterinary medicine.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. van Duijkeren E, Schwarz C, Bouchard D, et al. The use of aminoglycosides in animals within the EU: development of resistance in animals and possible impact on human and animal health: a review. J Antimicrob Chemother. 2019. PMID: 31002332. doi:10.1093/jac/dkz161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。